Pfizer's Phase III trial of gene therapy for Duchenne muscular dystrophy in young boys did not meet its primary endpoint of improving motor function. Despite this, the therapy's safety profile was manageable. Pfizer aims to share detailed results to enhance future research and care for DMD patients.